Applied Therapeutics Inc. (NASDAQ: APLT) stock jumped 6.45% on Monday to $1.98 against a previous-day closing price of $1.86. With 1.21 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.5 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $2.0300 whereas the lowest price it dropped to was $1.8400. The 52-week range on APLT shows that it touched its highest point at $2.18 and its lowest point at $0.50 during that stretch. It currently has a 1-year price target of $7.67. Beta for the stock currently stands at 1.88.
Top 5 EV Tech Stocks to Buy for 2023
The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".
Click Here to Download the FREE Report.
Sponsored
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of APLT was up-trending over the past week, with a rise of 16.47%, but this was up by 41.43% over a month. Three-month performance surged to 31.13% while six-month performance rose 107.94%. The stock gained 33.78% in the past year, while it has gained 160.53% so far this year. A look at the trailing 12-month EPS for APLT yields -1.24 with Next year EPS estimates of -1.08. For the next quarter, that number is -0.26. This implies an EPS growth rate of 47.10% for this year and 6.90% for next year.
Float and Shares Shorts:
At present, 79.04 million APLT shares are outstanding with a float of 57.23 million shares on hand for trading. On Aug 30, 2023, short shares totaled 1.48 million, which was 2.34% higher than short shares on Jul 30, 2023. In addition to Dr. Shoshana Shendelman Ph.D. as the firm’s Chair of the Board of Directors, Founder, Pres, CEO & Sec., Dr. Riccardo Perfetti M.D., Ph.D. serves as its Chief Medical Officer.
Institutional Ownership:
Through their ownership of 74.52% of APLT’s outstanding shares, institutional investors have majority control over the company. Other institutions hold 35.62% of APLT, in contrast to 20.25% held by mutual funds. Shares owned by individuals account for 12.81%. As the largest shareholder in APLT with 12.59% of the stake, Franklin Advisers, Inc. holds 7,946,732 shares worth 7,946,732. A second-largest stockholder of APLT, Propel Bio Management LLC, holds 4,757,382 shares, controlling over 7.54% of the firm’s shares. Alyeska Investment Group LP is the third largest shareholder in APLT, holding 4,431,406 shares or 7.02% stake. With a 16.51% stake in APLT, the FTIF SICAV – Biotechnology Discov is the largest stakeholder. A total of 10,420,578 shares are owned by the mutual fund manager. The Franklin Biotechnology Discovery, which owns about 7.96% of APLT stock, is the second-largest Mutual Fund holder. It holds 5,026,154 shares valued at 6.68 million. Fidelity Select Port. – Biotechno holds 4.18% of the stake in APLT, owning 2,639,536 shares worth 3.51 million.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on Jun 29, 2023, APLT reported revenue of $0.00 and operating income of -$21.52M. The EBITDA in the recently reported quarter was -$17.16M and diluted EPS was -$0.96.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for APLT since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential. With APLT analysts setting a high price target of $14.00 and a low target of $4.00, the average target price over the next 12 months is $7.67. Based on these targets, APLT could surge 607.07% to reach the target high and rise by 102.02% to reach the target low. Reaching the average price target will result in a growth of 287.37% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy.
Summary of Insider Activity:
Insiders traded APLT stock several times over the past three months with 0 Buys and 0 Sells. In these transactions, 0 shares were bought while 0 shares were sold. The number of buy transactions has increased to 12 while that of sell transactions has risen to 3 over the past year. The total number of shares bought during that period was 3,115,771 while 26,418 shares were sold.
